Advertisement

Wiener klinische Wochenschrift

, Volume 128, Supplement 2, pp 97–102 | Cite as

Diagnose, Therapie und Verlaufskontrolle der diabetischen Augenerkrankung

  • Stephan RaddaEmail author
  • Matthias Bolz
  • Stefan Egger
  • Vanessa Gasser-Steiner
  • Martina Kralinger
  • Stefan Mennel
  • Christoph Scholda
  • Ulrike Stolba
  • Andreas Wedrich
  • Katharina Krepler
leitlinien für die praxis
  • 231 Downloads

Zusammenfassung

Diabetes mellitus kann diabetische Retinopathie, diabetisches Makulaödem, Optikusneuropathie, Katarakt und Fehlfunktionen der äußeren Augenmuskeln verursachen. Die Inzidenz dieser Spätschäden korreliert mit der Dauer des Diabetes und mit dem Grad der metabolischen Kontrolle. Die Empfehlungen der Österreichischen Diabetesgesellschaft für Diagnose, Therapie und Nachkontrolle werden übersichtsweise und bezogen auf die jeweiligen Stadien der diabetischen Augenerkrankung präsentiert.

Schlüsselwörter

Diabetische Retinopathie Diabetisches Makulaödem Retinale Laserkoagulation Intravitreale operative Medikamentenapplikation Vitrektomie 

Diagnosis, treatment and monitoring of diabetic eye control

Summary

Diabetes mellitus can cause diabetic retinopathy, diabetic macular edema, optic neuropathy, cataract or dysfunction of the eye muscles. The incidence of these defects correlates with disease duration and quality of metabolic control. Recommendations of the Austrian Diabetes Association for diagnosis, therapeutic procedures and requirements for adequate follow up depending on stage of diabetic eye disease are summarized.

Keywords

Diabetic retinopathy Diabetic macular edema Retinal laser photocogulation Intravitreal therapy Vitrectomy 

Notes

Einhaltung ethischer Richtlinien

Interessenkonflikt

S. Radda hat von folgenden Unternehmen Forschungsunterstützung und/oder Honorare erhalten: Bayer (Travel Grants, Advisory Boards), Rayner (Travel Grants).

M. Bolz hat von Fa. Bayer einen Research Grant erhalten.

S. Egger hat Vorträge auf Veranstaltungen für die Firmen Allergan und Bayer gehalten und an Advisory Boards dieser Firmen teilgenommen.

V. Gasser-Steiner hat von folgenden Unternehmen, die auch fördernde Mitglieder der ÖDG sind, Forschungsunterstützung und/oder Honorare erhalten: Allergan, Bayer (Travel Grants, Advisory Boards).

M. Kralinger hat keinen Interessenkonflikt in Bezug auf diesen Artikel.

S. Mennel hat von folgenden Unternehmen, die auch fördernde Mitglieder der ÖDG sind, Forschungsunterstützung und/oder Honorare erhalten: Bayer Healthcare (Expert Opinion Meeting zum Thema Aflibercept), Novartis (Principal Investigator SALT study).

C. Scholda hat keinen Interessenkonflikt in Bezug auf diesen Artikel.

U. Stolba hat Vorträge auf Veranstaltungen von Bayer, Novartis und Allergan gehalten.

A. Wedrich hat keinen Interessenkonflikt in Bezug auf diesen Artikel.

Literatur

  1. 1.
    Khadem J, Buzney S, Alich K. Practice patterns in diabetic retinopathy: part 1: analysis of retinopathy follow-up. Arch Ophthalmol. 1999;117:815–20.CrossRefPubMedGoogle Scholar
  2. 2.
    McCarty C, Taylor K, McKay R, et al. Diabetic retinopathy: effects of national guidelines on the referral, examination and treatment practices of ophthalmologists and optometrists. Clin Experiment Ophthalmol. 2001;29:52–8.CrossRefPubMedGoogle Scholar
  3. 3.
    Wilkinson C, Ferris F, Klein R, et al. Proposed international clinical diabetic retinopathy and diabetic macular edema disease severity scales. Ophthalmology. 2003;110:1677–82.CrossRefPubMedGoogle Scholar
  4. 4.
    Hazin R, Colyer M, Lum F, et al. Revisiting Diabetes 2000: challenges in establishing nationwide diabetic retinopathy prevention programs. Am J Ophthalmol. 2011;152:723–9.CrossRefPubMedGoogle Scholar
  5. 5.
    Hammes H, Lemmen K Diagnostik, Therapie und Verlaufskontrolle der diabetischen Retinopathie und Makulopathie. Diabetes Stoffwechsel. 2002;11(Suppl 2):15–6.Google Scholar
  6. 6.
    Klein R, Klein BE, Moss SE. Epidemiology of proliferative diabetic retinopathy. Diabetes Care. 1992;15:1875–91.CrossRefPubMedGoogle Scholar
  7. 7.
    Zhang L, Krzentowski G, Albert A, et al. Risk of developing retinopathy in Diabetes Control and Complications Trial type 1 diabetic patients with good or poor metabolic control. Diabetes Care. 2001;24:1275–9.CrossRefPubMedGoogle Scholar
  8. 8.
    Stratton I, Kohner E, Aldington S, et al. UKPDS 50: risk factors for incidence and progression of retinopathy in Type II diabetes over 6 yrs from diagnosis. Diabetologia. 2001;44:156–63.CrossRefPubMedGoogle Scholar
  9. 9.
    Murphy RP, Nanda M, Plotnick L, et al. The relationship of puberty to diabetic retinopathy. Arch Ophthalmol. 1990;108(2):215–8.CrossRefPubMedGoogle Scholar
  10. 10.
    Effect of pregnancy on microvascular complications in the diabetes control and complications trial. The Diabetes Control and Complications Trial Research Group. Diabetes Care. 2000;23:1084–91.Google Scholar
  11. 11.
    Early worsening of diabetic retinopathy in the Diabetes Control and Complications Trial. Arch Ophthalmol. 1998;116:874–86.Google Scholar
  12. 12.
    Orchard T, Forrest K, Kuller L, et al. Lipid and blood pressure treatment goals for type 1 diabetes: 10-year incidence data from the Pittsburgh Epidemiology of Diabetes Complications Study. Diabetes Care. 2001;24:1053–9.CrossRefPubMedGoogle Scholar
  13. 13.
    Sen K, Misra A, Kumar A, et al. Simvastatin retards progression of retinopathy in diabetic patients with hypercholesterolemia. Diabetes Res Clin Pract. 2002;56:1–11.CrossRefPubMedGoogle Scholar
  14. 14.
    UK Prospective Diabetes Study Group. Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38. BMJ. 1998;317:703–13.CrossRefPubMedCentralGoogle Scholar
  15. 15.
    Nasr C, Hoogwerf B, Faiman C, et al. United Kingdom Prospective Diabetes Study (UKPDS). Effects of glucose and blood pressure control on complications of type 2 diabetes mellitus. Cleve Clin J Med. 1999;66:247–53.CrossRefPubMedGoogle Scholar
  16. 16.
    Davis M, Fisher M, Gangnon R, et al. Risk factors for high-risk proliferative diabetic retinopathy and severe visual loss: early Treatment Diabetic Retinopathy Study Report Number 18. Invest Ophthalmol Vis Sci. 1998;39:233–52.PubMedGoogle Scholar
  17. 17.
    Kinyoun J, Barton F, Fisher M, et al. Detection of diabetic macular edema. Ophthalmoscopy versus photography – Early Treatment Diabetic Retinopathy Study Report Number 5. The ETDRS Research Group. Ophthalmology. 1989;96:746–50.CrossRefPubMedGoogle Scholar
  18. 18.
    Gonzalez Villalpando C, Gonzalez Villalpando ME, Martinez Diaz S, et al. A diabetic retinopathy screening program as a strategy for blindness prevention. Arch Med Res. 1997;28:129–35.PubMedGoogle Scholar
  19. 19.
    Bolz M, Schmidt-Erfurth U, Deak G, et al. Optical coherence tomographic hyperreflective foci: a morphologic sign of lipid extravasation in diabetic macular edema. Ophthalmology. 2009;116:914–20.CrossRefPubMedGoogle Scholar
  20. 20.
    Baskin DE. Optical coherence tomography in diabetic macular edema. Curr Opin Ophthalmol. 2010;21:172–7.CrossRefPubMedGoogle Scholar
  21. 21.
    Tangelder GJ, Van der Heijde RG, Polak BC, et al. Precision and reliability of retinal thickness measurements in foveal and extrafoveal areas of healthy and diabetic eyes. Invest Ophthalmol Vis Sci. 2008;49:2627–34.CrossRefPubMedGoogle Scholar
  22. 22.
    Browning DJ, Fraser CM. The predictive value of patient and eye characteristics on the course of subclinical diabetic macular edema. Am J Ophthalmol. 2008;145:149–54.CrossRefPubMedGoogle Scholar
  23. 23.
    Bolz M, Ritter M, Schneider M, et al. A systematic correlation of angiography and high-resolution optical coherence tomography in diabetic macular edema. Ophthalmology. 2009;116:66–72.CrossRefPubMedGoogle Scholar
  24. 24.
    Fluorescein angiographic risk factors for progression of diabetic retinopathy. ETDRS report number 13. Early Treatment Diabetic Retinopathy Study Research Group. Ophthalmology. 1991;98 Suppl 5:834–40.Google Scholar
  25. 25.
    Pandit RJ, Taylor R. Quality assurance in screening for sight-threatening diabetic retinopathy. Diabet Med. 2002;19:285–91.CrossRefPubMedGoogle Scholar
  26. 26.
    Kuo HK, Hsieh HH, Liu RT. Screening for diabetic retinopathy by one-field, non-mydriatic, 45 degrees digital photography is inadequate. Ophthalmologica. 2005;219:292–6.CrossRefPubMedGoogle Scholar
  27. 27.
    Case reports to accompany Early Treatment Diabetic Retinopathy Study Reports 3 and 4. The Early Treatment Diabetic Retinopathy Study Research Group. Int Ophthalmol Clin. 1987;27:273–333.Google Scholar
  28. 28.
    Fundus photographic risk factors for progression of diabetic retinopathy. ETDRS report number 12. Early Treatment Diabetic Retinopathy Study Research Group. Ophthalmology. 1991;5:823–33.Google Scholar
  29. 29.
    Lindgren G, Lindblom B. Causes of vitreous hemorrhage. Curr Opin Ophthalmol. 1996;7:13–9.CrossRefPubMedGoogle Scholar
  30. 30.
    Fong D, Ferris F, Davis M, et al. Causes of severe visual loss in the early treatment diabetic retinopathy study: ETDRS report no. 24. Early Treatment Diabetic Retinopathy Study Research Group. Am J Ophthalmol. 1999;127(2):137–41.CrossRefPubMedGoogle Scholar
  31. 31.
    Antcliff R, Marshall J. The pathogenesis of edema in diabetic maculopathy. Semin Ophthalmol. 1999;14:223–32.CrossRefPubMedGoogle Scholar
  32. 32.
    CDC Diabetes Cost-effectiveness Group. Cost-effectiveness of intensive glycemic control, intensified hypertension control, and serum cholesterol level reduction for type 2 diabetes. JAMA. 2002;287:2542–51.CrossRefGoogle Scholar
  33. 33.
    Treatment techniques and clinical guidelines for photocoagulation of diabetic macular edema. Early Treatment Diabetic Retinopathy Study Report Number 2. Early Treatment Diabetic Retinopathy Study Research Group. Ophthalmology. 1987;94:761–74.Google Scholar
  34. 34.
    Kohner E, Stratton I, Aldington S, et al. Relationship between the severity of retinopathy and progression to photocoagulation in patients with Type 2 diabetes mellitus in the UKPDS (UKPDS 52). Diabet Med. 2001;18:178–84.CrossRefPubMedGoogle Scholar
  35. 35.
    The effect of intensive diabetes treatment on the progression of diabetic retinopathy in insulin-dependent diabetes mellitus. The Diabetes Control and Complications Trial. Arch Ophthalmol. 1995;113:36–51.Google Scholar
  36. 36.
    Squirrell D, Bhola R, Bush J, et al. A prospective, case controlled study of the natural history of diabetic retinopathy and maculopathy after uncomplicated phacoemulsification cataract surgery in patients with type 2 diabetes. Br J Ophthalmol. 2002;86:565–71.CrossRefPubMedPubMedCentralGoogle Scholar
  37. 37.
    Flesner P, Sander B, Henning V, et al. Cataract surgery on diabetic patients. A prospective evaluation of risk factors and complications. Acta Ophthalmol Scand. 2002;80:19–24.CrossRefPubMedGoogle Scholar
  38. 38.
    Chung J, Kim MY, Kim HS, et al. Effect of cataract surgery on the progression of diabetic retinopathy. J Cataract Refract Surg. 2002;28:626–30.CrossRefPubMedGoogle Scholar
  39. 39.
    Cunha-Vaz J. Lowering the risk of visual impairment and blindness. Diabet Med. 1998;15(Suppl 4):S47–50.CrossRefPubMedGoogle Scholar
  40. 40.
    Aiello LP, Beck RW, Bressler NM, et al. Rationale for the diabetic retinopathy clinical research network treatment protocol for center-involved diabetic macular edema. Ophthalmology. 2011;118:e5–14.CrossRefPubMedPubMedCentralGoogle Scholar
  41. 41.
    Elman MJ, Aiello LP, Beck RW, et al. Randomized trial evaluating ranibizumab plus prompt or deferred laser or triamcinolone plus prompt laser for diabetic macular edema. Ophthalmology. 2010;117:1064–77.CrossRefPubMedPubMedCentralGoogle Scholar
  42. 42.
    Nguyen QD, Shah SM, Khwaja AA, et al. Two-year outcomes of the ranibizumab for edema of the mAcula in diabetes (READ-2) study. Ophthalmology. 2010;117:2146–51.CrossRefPubMedGoogle Scholar
  43. 43.
    Massin P, Bandello F, Garweg JG, et al. Safety and efficacy of ranibizumab in diabetic macular edema (RESOLVE Study): a 12-month, randomized, controlled, double-masked, multicenter phase II study. Diabetes Care. 2010;33:2399–405.CrossRefPubMedPubMedCentralGoogle Scholar
  44. 44.
    Elman MJ, Bressler NM, Qin H, et al. Expanded 2-year follow-up of ranibizumab plus prompt or deferred laser or triamcinolone plus prompt laser for diabetic macular edema. Ophthalmology. 2011;118:609–14.CrossRefPubMedPubMedCentralGoogle Scholar
  45. 45.
    Nguyen QD, Brown DM, Marcus DM, et al. Ranibizumab for diabetic macular edema: results from 2 phase III randomized trials: RISE and RIDE. Ophthalmology. 2012;119:789–801.CrossRefPubMedGoogle Scholar
  46. 46.
    Elman MJ, Ayala A, Bressler NM, Browning D, Flaxel CJ, Glassman AR, Jampol LM, Stone TW, Diabetic Retinopathy Clinical Research Network. Intravitreal Ranibizumab for diabetic macular edema with prompt versus deferred laser treatment: 5-year randomized trial results. Ophthalmology. 2015;122:375–81. doi: 10.1016/j.ophtha.2014.08.047.CrossRefPubMedPubMedCentralGoogle Scholar
  47. 47.
    Korobelnik JF, Do DV, Schmidt-Erfurth U, Boyer DS, Holz FG, Heier JS, Midena E, Kaiser PK, Terasaki H, Marcus DM, Nguyen QD, Jaffe GJ, Slakter JS, Simader C, Soo Y, Schmelter T, Yancopoulos GD, Stahl N, Vitti R, Berliner AJ, Zeitz O, Metzig C, Brown DM. Intravitreal aflibercept for diabetic macular edema. Ophthalmology. 2014;121(11):2247–54. doi: 10.1016/j.ophtha.2014.05.006.CrossRefPubMedGoogle Scholar
  48. 48.
    Diabetic Retinopathy Clinical Research Network, Wells JA, Glassman AR, Ayala AR, Jampol LM, Aiello LP, Antoszyk AN, Arnold-Bush B, Baker CW, Bressler NM, Browning DJ, Elman MJ, Ferris FL, Friedman SM, Melia M, Pieramici DJ, Sun JK, Beck RW. Aflibercept, bevacizumab, or ranibizumab for diabetic macular edema. N Engl J Med. 2015;372:1193–203. doi: 10.1056/NEJMoa1414264.CrossRefGoogle Scholar
  49. 49.
    Mitchell P, Bandello F, Schmidt-Erfurth U, et al. The RESTORE study: ranibizumab monotherapy or combined with laser versus laser monotherapy for diabetic macular edema. Ophthalmology. 2011;118:615–25.CrossRefPubMedGoogle Scholar
  50. 50.
    Boyer DS, Yoon YH, Belfort R Jr, Bandello F, Maturi RK, Augustin AJ, Li XY, Cui H, Hashad Y, Whitcup SM, Ozurdex MEAD Study Group. Three-year, randomized, sham-controlled trial of dexamethasone intravitreal implant in patients with diabetic macular edema. Ophthalmology. 2014;121:1904–14. doi: 10.1016/j.ophtha.2014.04.024.CrossRefPubMedGoogle Scholar
  51. 51.
    Campochiaro PA, Brown DM, Pearson A, Ciulla T, Boyer D, Holz FG, Tolentino M, Gupta A, Duarte L, Madreperla S, Gonder J, Kapik B, Billman K, Kane FE. Long-term benefit of sustained-delivery fluocinolone acetonide vitreous inserts for diabetic macular edema. Ophthalmology. 2011;118:626–35.e2. doi: 10.1016/j.ophtha.2010.12.028.CrossRefPubMedGoogle Scholar
  52. 52.
    Preliminary report on effects of photocoagulation therapy. The Diabetic Retinopathy Study Research Group. Am J Ophthalmol. 1976;81:383–96.Google Scholar
  53. 53.
    Techniques for scatter and local photocoagulation treatment of diabetic retinopathy: early Treatment Diabetic Retinopathy Study Report no. 3. The Early Treatment Diabetic Retinopathy Study Research Group. Int Ophthalmol Clin. 1987;27:254–64.Google Scholar
  54. 54.
    Googe J, Brucker AJ, Bressler NM, et al. Randomized trial evaluating short-term effects of intravitreal ranibizumab or triamcinolone acetonide on macular edema after focal/grid laser for diabetic macular edema in eyes also receiving panretinal photocoagulation. Retina. 2011;31:1009–27.CrossRefPubMedGoogle Scholar
  55. 55.
    Ferris F. Early photocoagulation in patients with either type I or type II diabetes. Trans Am Ophthalmol Soc. 1996;94:505–37.PubMedPubMedCentralGoogle Scholar
  56. 56.
    Bodanowitz S, Hesse L, Weinand F, et al. Vitrectomy in diabetic patients with a blind fellow eye. Acta Ophthalmol Scand. 1996;74:84–8.CrossRefPubMedGoogle Scholar
  57. 57.
    Filho JA, Messias A, Almeida FP, et al. Panretinal photocoagulation (PRP) versus PRP plus intravitreal ranibizumab for high-risk proliferative diabetic retinopathy. Acta Ophthalmol. 2011;89:567–72.CrossRefGoogle Scholar
  58. 58.
    Kohner EM, Barry PJ. Prevention of blindness in diabetic retinopathy. Diabetologia. 1984;26:173–9.CrossRefPubMedGoogle Scholar
  59. 59.
    Rand LI, Prud’homme GJ, Ederer F, et al. Factors influencing the development of visual loss in advanced diabetic retinopathy. Diabetic Retinopathy Study (DRS) Report No. 10. Invest Ophthalmol Vis Sci. 1985;26:983–91.PubMedGoogle Scholar
  60. 60.
    Dogru M, Nakamura M, Inoue M, et al. Long-term visual outcome in proliferative diabetic retinopathy patients after panretinal photocoagulation. Jpn J Ophthalmol. 1999;43:217–24.CrossRefPubMedGoogle Scholar

Copyright information

© Springer-Verlag Wien 2016

Authors and Affiliations

  • Stephan Radda
    • 1
    • 9
    Email author
  • Matthias Bolz
    • 2
    • 9
  • Stefan Egger
    • 3
    • 9
  • Vanessa Gasser-Steiner
    • 4
    • 9
  • Martina Kralinger
    • 5
    • 9
  • Stefan Mennel
    • 6
    • 9
  • Christoph Scholda
    • 7
    • 9
  • Ulrike Stolba
    • 8
    • 9
  • Andreas Wedrich
    • 4
    • 9
  • Katharina Krepler
    • 7
    • 9
  1. 1.Abteilung für AugenheilkundeHanuschkrankenhausWienÖsterreich
  2. 2.Abteilung für AugenheilkundeAllgemeines Krankenhaus LinzLinzÖsterreich
  3. 3.Universitätsklinik für AugenheilkundeLandeskrankenhaus Salzburg – Universitätsklinikum SalzburgSalzburgÖsterreich
  4. 4.Universitätsklinik für AugenheilkundeMedizinische Universität GrazGrazÖsterreich
  5. 5.Universitätsklinik für AugenheilkundeMedizinische Universität InnsbruckInnsbruckÖsterreich
  6. 6.Abteilung für AugenheilkundeLandeskrankenhaus FeldkirchFeldkirchÖsterreich
  7. 7.Universitätsklinik für AugenheilkundeMedizinische Universität WienWienÖsterreich
  8. 8.Abteilung für AugenheilkundeKrankenanstalt Rudolfstiftung der Stadt WienWienÖsterreich
  9. 9.NetzhautkommissionÖsterreichische Ophthalmologische GesellschaftWienÖsterreich

Personalised recommendations